An analysis of clinical effectiveness of electrochemotherapy in the treatment of advanced metastatic malignant melanoma performed in the eastern part of Central Europe: a single-centre experience.
cutaneous melanoma
electrochemotherapy
electroporation
in-transit metastases
Journal
Postepy dermatologii i alergologii
ISSN: 1642-395X
Titre abrégé: Postepy Dermatol Alergol
Pays: Poland
ID NLM: 101168357
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
02
11
2021
accepted:
28
12
2021
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
12
8
2022
Statut:
ppublish
Résumé
Patients with cutaneous malignant melanoma (MM), in case of non-resectability of the lesions, have only a limited pool of the available treatment options. In recent years especially electrochemotherapy (ECT) has become an increasingly important therapy in locoregionally advanced MM. In this study an analysis of the ECT treatment of locoregionally advanced malignant melanoma was presented. Six ECT cycles in 5 patients were performed in the Wroclaw Comprehensive Cancer Centre. Treatment response, long-term observation, technical data downloaded from electroporator and photographs taken before and after the ECT were assessed in the analysis. In total, 200 nodules in 5 patients were treated with ECT in palliative intent. After 5 out of 6 ECT cycles, the particular clinical response has been observed. Four patients with primary unresectable lesions underwent 11 surgeries of the cutaneous metastases. In long-term follow-up in 2 patients, of whom one died 19 months after the ECT, the disease progressed and in another two, no recurrence was observed. ECT is an encouraging therapy for patients in whom the recurrent cutaneous melanoma cannot be treated with other methods, however, access to this method in eastern part of Central Europe is limited. The presented study seems to confirm the usefulness of this palliative approach in a specific group of patients suffering from cutaneous MM.
Identifiants
pubmed: 35950133
doi: 10.5114/ada.2022.117528
pii: 47327
pmc: PMC9326931
doi:
Types de publication
Journal Article
Langues
eng
Pagination
559-564Informations de copyright
Copyright: © 2022 Termedia Sp. z o. o.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Clin Cosmet Investig Dermatol. 2016 Nov 23;9:451-459
pubmed: 27920565
Ann Surg Oncol. 2008 Aug;15(8):2215-22
pubmed: 18498012
Actas Dermosifiliogr. 2017 Mar;108(2):91-97
pubmed: 27769538
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Actas Dermosifiliogr. 2015 May;106(4):285-91
pubmed: 25512237
Pharmacotherapy. 2017 Mar;37(3):319-333
pubmed: 28052356
Br J Dermatol. 2017 Jun;176(6):1475-1485
pubmed: 28118487
Adv Med Sci. 2015 Mar;60(1):83-8
pubmed: 25596540
Ther Clin Risk Manag. 2008 Apr;4(2):541-8
pubmed: 18728828
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1053-62
pubmed: 25491923
J Cutan Med Surg. 2006 May-Jun;10(3):115-21
pubmed: 17241586
Int J Surg. 2018 Apr;52:110-119
pubmed: 29474886
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Curr Oncol Rep. 2019 Nov 6;21(11):98
pubmed: 31696407
J Med Life. 2015 Apr-Jun;8(2):132-41
pubmed: 25866567
Acta Oncol. 2018 Jul;57(7):874-882
pubmed: 29577784
Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):280-90
pubmed: 11586069
CA Cancer J Clin. 2016 Nov 12;66(6):460-480
pubmed: 27232110
Cancer. 1995 Jan 15;75(2 Suppl):707-14
pubmed: 7804999
Eur J Cancer. 2020 Feb;126:159-177
pubmed: 31866016
Cancer Nurs. 2017 Jan/Feb;40(1):E45-E53
pubmed: 26863052
Eur J Cancer. 2020 Oct;138:30-40
pubmed: 32836172
Arch Dermatol. 2009 Dec;145(12):1415-27
pubmed: 20026852
Dermatol Ther. 2014 May-Jun;27(3):148-52
pubmed: 24903471
J Eur Acad Dermatol Venereol. 2014 Apr;28(4):424-32
pubmed: 23506474
Contemp Oncol (Pozn). 2018;22(1):8-13
pubmed: 29692657